LABP - Landos Biopharma names industry veteran Gregory Oakes as new president and CEO

Landos Biopharma (NASDAQ:LABP) +5% on Tuesday has announced the appointment of Gregory Oakes as its president and chief effective officer, effective immediately. Oakes most recently served as president, North America, EVP and member of the executive committee of Vifor Pharma and previously held leadership roles at Amgen, Celgene Corporation, Novartis International AG and Schering-Plough The company told Tim M. Mayleben, who has been serving as interim president and CEO since November 2021, will continue to serve as a member of its Board of Directors. Earlier: Landos Biopharma GAAP EPS of -$0.37

For further details see:

Landos Biopharma names industry veteran Gregory Oakes as new president and CEO